Keros Therapeutics (KROS) Share-based Compensation (2019 - 2025)

Keros Therapeutics (KROS) has 7 years of Share-based Compensation data on file, last reported at $7.3 million in Q4 2025.

• For the quarter ending Q4 2025, Share-based Compensation fell 20.6% year-over-year to $7.3 million; the trailing twelve-month figure through Dec 2025 stood at $28.7 million (down 17.71% YoY), and the FY2025 full-year result was $28.7 million, down 17.71% from the prior year.
• Share-based Compensation for Q4 2025 stood at $7.3 million, up from $4.0 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $9.2 million in Q4 2024 and bottomed at $2.5 million in Q1 2021.
• The 5-year median for Share-based Compensation is $6.4 million (2023), against an average of $6.1 million.
• The widest annual swing landed in 2021, when Share-based Compensation jumped 20683.33%; it then tumbled 54.79% in 2025.
• A 5-year view of Share-based Compensation shows it stood at $3.3 million in 2021, then soared by 44.04% to $4.7 million in 2022, then soared by 54.32% to $7.3 million in 2023, then increased by 25.61% to $9.2 million in 2024, then declined by 20.6% to $7.3 million in 2025.
• The last three Share-based Compensation figures came in at $7.3 million (Q4 2025), $4.0 million (Q3 2025), and $8.5 million (Q2 2025), per Business Quant data.

Peer Comparison